FDA warning letters to peptide sellers follow a clear pattern. From 2024 to 2026, FDA wrote to online sellers, telehealth companies and compounders about semaglutide, tirzepatide, retatrutide and other peptides. This guide sorts the violations FDA cites into five groups. We read each letter on fda.gov on November 17, 2026.
Quick answer: FDA warning letters to peptide and GLP-1 sellers cite five recurring problems: unapproved new drugs, research-use labels contradicted by human-use marketing, misbranding, compounding outside sections 503A and 503B, and salt forms of semaglutide. A warning letter states FDA’s position; it is not a court ruling. The letters show that FDA reads intended use from the whole website, not from the label alone.
This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.
What is an FDA warning letter?
FDA’s Regulatory Procedures Manual says warning letters “are issued only for violations of regulatory significance” and are meant “to achieve voluntary compliance and to establish prior notice.” It also says a warning letter “is informal and advisory” and that FDA does not consider warning letters to be final agency action (FDA, 2024). The recipient is asked to respond, either with a plan to correct the problems or with its reasons for disagreeing (FDA, 2024). The manual adds that warning letters are posted publicly on fda.gov.
Violation 1: unapproved new drugs
A new drug may not be introduced into interstate commerce unless an FDA-approved application is in effect for it. In letters to online sellers, FDA first finds that the products are drugs because they are intended for use in the “diagnosis, cure, mitigation, treatment, or prevention of disease.” It then finds they are new drugs and states that no approved application covers them. In the August 2026 letter to TXP Innovations LLC dba Tex Peptides, FDA wrote: “No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.” Nine of the 11 letters in Table 1 cite sections 505(a) and 301(d). The other two, about the marketing of compounded drugs, cite misbranding only.
Violation 2: research-use labels contradicted by human-use marketing
Many recipients labeled their products for research. The December 2024 letter to Summit Research Peptides quotes “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY.” The February 2025 letter to USApeptide.com quotes “research use only” and “not for human consumption.” The March 2026 letter to Gram Peptides quotes “Research Use Only.” The August 2026 letters to Peptide Partners LLC and Tex Peptides quote “not for human or veterinary use.” In each case, FDA wrote that evidence from the seller’s website established that the products were intended to be drugs for human use.
The legal basis is intended use. Under 21 CFR 201.128, intended use means the “objective intent” of the people responsible for a product, which “may be shown by such persons’ expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article.” FDA’s GLP-1 page says it has warned companies that sold semaglutide, tirzepatide, retatrutide, survodutide or mazdutide products “falsely labeled” for research purposes or not for human consumption (FDA, 2026). The August 2026 letters also list SS-31, tesamorelin and PT-141.
Violation 3: misbranding
Misbranding appears in two forms. First, letters to sellers of prescription drugs state that the labeling “fails to bear adequate directions for use” under section 502(f)(1). The letters to USApeptide.com and Nomida.biz add that the websites misbrand prescription drugs under section 503(b)(1), and that dispensing without a prescription results in a drug being misbranded while held for sale, in violation of section 301(k).
Second, letters about compounded drugs cite false or misleading claims under sections 502(a) and 502(bb). The September 2025 letter to Hims & Hers Health, Inc. dba Hims quotes “Same active ingredient as Ozempic and Wegovy.” FDA wrote: “Your claims imply that your products are the same as an FDA-approved product when they are not.” The February 2026 letter to MEDVi, LLC dba MEDVi also objected to a label that suggested the company was the compounder. On March 3, 2026, FDA announced 30 warning letters to telehealth companies and said: “Compounded drugs are also not the same as generic drugs, which are FDA-approved” (FDA, 2026).
Violation 4: compounding outside sections 503A and 503B
A compounded drug is exempt from the approval requirement only when it meets the conditions of section 503A or 503B. The September 2025 letter to ASN-LABS found that compounded retatrutide met neither. Under 503A, retatrutide “is not the subject of an applicable USP or NF monograph,” “is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.” Under 503B, it does not appear on the 503B bulks list and is not used to compound a drug on the shortage list.
The April 2026 letter to ProRx LLC, a registered outsourcing facility, found that its tirzepatide products were not eligible for the 503B exemptions because “tirzepatide does not appear on the 503B bulks list” and was not used to compound a drug on FDA’s shortage list. That letter also cited insanitary conditions and failures of current good manufacturing practice under section 501(a)(2). Our guide to 503A vs 503B compounding explains both sets of conditions.
Violation 5: salt forms of semaglutide
FDA states that some compounders may sell semaglutide salt forms. “These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients” from the ones in approved drugs, and FDA is “not aware of any lawful basis for their use in compounding” (FDA, 2026). FDA made the point in a warning letter as early as October 2, 2023, writing that the salt forms “are different active ingredients than are used in the FDA-approved drugs, which contain the base form of semaglutide” (FDA, 2023). Our page on compounded semaglutide covers the wider rules.
Which letters show these patterns?
Table 1 lists the letters we read. Company names are as FDA gives them, and each links to the letter on fda.gov. FDA also announced on December 17, 2024 that it had posted four letters to companies for introducing unapproved GLP-1 products, including Summit Research Peptides (FDA, 2024).
Example FDA warning letters to peptide and GLP-1 sellers, 2024 to 2026
| Date | Company, as named by FDA | Products | Issue FDA cited |
|---|---|---|---|
| April 24, 2024 | www.dashpct.com | Oral semaglutide tablets | Unapproved new drugs; misbranding for lack of adequate directions for use |
| September 12, 2024 | Nomida.biz | Semaglutide, tirzepatide | Unapproved new drugs; misbranding, including dispensing without a prescription |
| December 10, 2024 | Summit Research Peptides | Research-labeled semaglutide, tirzepatide, retatrutide, cagrilintide, mazdutide | Unapproved new drugs despite research-use labels |
| February 26, 2025 | USApeptide.com | Research-labeled semaglutide, tirzepatide | Unapproved new drugs and misbranding despite research-use labels |
| September 9, 2025 | ASN-LABS | Compounded retatrutide; semaglutide, tirzepatide | Fails 503A and 503B conditions; claims implying sameness with an approved drug |
| September 9, 2025 | Hims & Hers Health, Inc. dba Hims | Compounded semaglutide | Misbranding: claims implying sameness with approved drugs |
| February 20, 2026 | MEDVi, LLC dba MEDVi | Compounded semaglutide, tirzepatide | Misbranding: implied compounder identity and sameness claims |
| March 31, 2026 | Gram Peptides | Research-labeled retatrutide, tirzepatide | Unapproved new drugs despite research-use labels |
| April 7, 2026 | ProRx LLC | Tirzepatide compounded by an outsourcing facility | Not on 503B bulks list or shortage list; insanitary conditions and manufacturing failures |
| August 24, 2026 | Peptide Partners LLC | Research-labeled GLP-1 products, SS-31, tesamorelin, PT-141 | Unapproved new drugs despite research-use labels |
| August 24, 2026 | TXP Innovations LLC dba Tex Peptides | Research-labeled GLP-1 products, SS-31, tesamorelin, PT-141 | Unapproved new drugs despite research-use labels |
What do the letters mean for research-labeled peptides?
The letters do not say that research use is unlawful. They say a label does not decide intended use when the rest of the evidence points to people. The same reasoning appears in our pages on BPC-157 and retatrutide, and in our guide to what research use only means. Research-grade material is not an alternative to an approved medicine. Our products are for laboratory research use only, not for human or veterinary use.
Frequently asked questions about FDA warning letters to peptide sellers
Is a warning letter a legal ruling?
No. FDA calls a warning letter informal and advisory and does not treat it as final agency action. It states FDA’s position and asks the company to respond.
Does a “research use only” label protect a seller?
Not by itself. In the letters we read, FDA found that website evidence showed the products were intended for human use, despite research-use labels.
Which peptides appear in these letters?
In the letters we read: semaglutide, tirzepatide, retatrutide, cagrilintide, mazdutide, SS-31, tesamorelin and PT-141.
Why does FDA object to “same active ingredient” claims?
FDA says they imply a compounded product is the same as an FDA-approved one. Compounded drugs are not FDA-approved.
What to know now
- Most common finding: unapproved new drugs under sections 505(a) and 301(d).
- Research labels: did not change FDA’s finding when website evidence showed human use.
- Misbranding: inadequate directions, sale without a prescription, and sameness claims.
- Compounding: retatrutide fails 503A and 503B; tirzepatide is not on the 503B bulks list.
- Salt forms: FDA says semaglutide sodium and acetate are different active ingredients.
- Status: warning letters are informal and advisory, not court rulings.
What we’re watching
New FDA warning letters to sellers of research-labeled peptides, which we will add to Table 1 after reading them on fda.gov. FDA’s final decision on its April 2026 proposal to leave semaglutide, tirzepatide and liraglutide off the 503B bulks list. And any FDA statement on the outcome of the letters listed here.